Diabetes Deck 2 Flashcards

(51 cards)

1
Q

Glucagon-Like peptide-1 agonist (GLP-1

Agonists) - Agents

A

liraglutide (Victoza™), dulaglutide (Trulicity™), exenatide (Byetta™), semaglutide
(Ozempic™, Rybelsus™ - oral)
○ The “-glutides”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Glucagon-Like peptide-1 agonist (GLP-1

Agonists) Moa

A

: increase insulin release in the presence of elevated glucose,
decreases glucagon secretion, and delays gastric emptying (reducing the rate at which
postprandial glucose appears in circulation); decreased appetite

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Glucagon-Like peptide-1 agonist (GLP-1

Agonists) - Efficacy

A

○ Nausea, decreased appetite, vomiting, indigestion, diarrhea
○ Headache
○ Injection site reactions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Glucagon-Like peptide-1 agonist (GLP-1

Agonists) - SE

A

○ Pancreatitis

○ Gallstones/Cholecystitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Glucagon-Like peptide-1 agonist (GLP-1

Agonists) - Serious SE

A

○ A1C, Blood glucose

○ Weight

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Glucagon-Like peptide-1 agonist (GLP-1

Agonists) Contraindications

A

○ History of medullary thyroid carcinoma

○ History of multiple endocrine neoplasia syndrome type II

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Glucagon-Like peptide-1 agonist (GLP-1

Agonists) - place in therapy

A

○ Common agent used after metformin
○ Benefit in patients with ASCVD
○ Beneficial for weight loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Glucagon-Like peptide-1 agonist (GLP-1

Agonists) - Administration

A

Technique varies across agents
■ Injection technique for Victoza and Ozempic are similar to insulin pens
■ Trulicity is a self contained system
■ Bydureon pen is being discontinued; Kit is hard to use

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Glucagon-Like peptide-1 agonist (GLP-1

Agonists) - Pearls

A

Lower dose is started and titrated to higher dose to reduce GI issues. Starting doses are generally
not sufficient for BG control/management
○ Generally one of these agents is covered by insurance, but varies
○ Trulicity and Ozempic are once weekly
○ Rybelsus is oral but not well covered yet
○ Bydureon kit is hard to set up – if only agent covered can be helpful to train a family
member/Home Health to assist with administration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Glucagon-Like peptide-1 agonist (GLP-1

Agonists) - Monitoring

A

○ A1C, Blood glucose

○ Weight

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Sodium-Glucose Cotransporter 2 Inhibitors

(SGLT2-inhibitors) - Agents

A

canagliflozin (Invokana™), empagliflozin (Jardiance™), dapagliflozin (Farxiga™)
○ The “-flozins”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Sodium-Glucose Cotransporter 2 Inhibitors

(SGLT2-inhibitors) - MOA

A

Inhibits glucose reabsorption in the kidneys through inhibition of
sodium-glucose cotransporter 2; Decreases serum glucose concentrations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Sodium-Glucose Cotransporter 2 Inhibitors

(SGLT2-inhibitors) Efficacy

A

○ Additional benefit in chronic kidney disease
○ Additional benefit in cardiovascular disease: empagliflozin, canagliflozin (ASCVD); empagliflozin,
canagliflozin, and dapagliflozin (HF)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Sodium-Glucose Cotransporter 2 Inhibitors

(SGLT2-inhibitors) - SE

A

○ Genitourinary infections (UTIs, Yeast Infections)

○ Increased urination

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Sodium-Glucose Cotransporter 2 Inhibitors

(SGLT2-inhibitors) - Serious SE

A
○ Kidney Injury
○ Hypovolemia
○ Limb/Foot amputations
○ Bone fractures (canagliflozin)
○ DKA risk
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Sodium-Glucose Cotransporter 2 Inhibitors

(SGLT2-inhibitors) Monitoring

A

○ Blood Pressure
○ A1C, Blood glucose
○ Volume status

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Sodium-Glucose Cotransporter 2 Inhibitors

(SGLT2-inhibitors) Contraindications

A

○ Dialysis

○ Acute Kidney Injury

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Sodium-Glucose Cotransporter 2 Inhibitors

(SGLT2-inhibitors) - Place in therapy

A

○ Common agent used after metformin
○ Benefit in patients with ASCVD and/or HF or CKD
○ Benefit for weight loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Sodium-Glucose Cotransporter 2 Inhibitors

(SGLT2-inhibitors) - Administration

A

○ Take before the first meal of the day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Sodium-Glucose Cotransporter 2 Inhibitors

(SGLT2-inhibitors) Pearls

A

○ Generally avoided in older patients due to infection risk
○ Can be expensive if not covered by insurance but benefits with ASCVD/HF/CKD pushing for more
coverage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Insulin General fact

A

Replaces the insulin the body produces to help with blood glucose uptake in the tissues
● Many, many different products
● Human and synthetic insulin products
● Differ based on molecular structure which determines duration, onset, and peak of these
agents

22
Q

Insulin Dosing regimens

A

○ Long + Rapid Acting/Short acting

○ Intermediate BID

23
Q

Insulin - Available In

A

pens, vials, and IV
○ Generally stored in the refrigerator but can be stored at rooom temp when in use
○ Beyond use dates vary when removed from refrigeration

24
Q

Insulin - Administered

A

subcutaneously in the thighs, arms, buttocks, or abdomen (most common)

25
Insulin - Adminsitration schedule
e depends on the product
26
Insulin Monitoring
○ A1C ○ Blood sugars ○ Hypoglycemia
27
Insulin - Adverse Effects
○ Hypoglycemia ○ Injection site reactions ○ Weight gain
28
Insulin - Dosing
○ Generally guided by blood glucose ○ High fasting - Adjust basal ○ High 2 hour PP - Adjust mealtime
29
Insulin - Short Acting - Agents
○ Insulin glulisine (Apidra™) ○ Insulin Lispro (Humalog™) ○ Insulin Aspart (Novolog™)
30
Insulin - Short Acting generally administered
10-15 minutes | before a meal or immediately after
31
Gluisine Onset Peak Duration
``` Onset ~10 - 20 minutes Peak 0.5- 1.5 hours Duration ~5 hours ```
32
Humalog Onset Peak Duration
``` Onset 15-30 min Peak 0.5-2.5 hours Duration 3-6.5 hours ```
33
Insulin - Long Acting Agents
Agents: ○ Insulin detemir (Levemir™) ○ Insulin glargine (Lantus™/Basaglar™) ○ Insulin glargine (Toujeo™) 300 units/mL ○ Insulin degludec (Tresiba™) -- Ultra-long acting
34
Insulin - Long Acting Gneral dosing
Generally once daily, but will sometimes see BID dosing
35
Levemier onset peak duration
Onset 1-2 hours Peak 6-8 hours Duration 7.6 - 24+
36
Lantus onset peak duration
Onset 1 to 1.5 hours Peak None Duration 24 hours (11-24+ hours)
37
Toujeo Onset peak duration
O - 5 hours P - None D - >24 hours
38
Tresiba onset peak duration
O - 30 to 90 min P - None D - At least 42 hours
39
Insulin - Ultra Rapid Acting - Agents
○ Fiasp™ (insulin aspart) | ○ Lyumjev™ (insulin lispro-aabc)
40
Lyumjev - Formulated
with niacinamide for faster absorption ○ Inject within 20 minutes after the start of the meal
41
Fiasp - Inject at the
start of the meal or within 20 min after the start of the meal
42
Insulin - Short Acting Regular - Agents
○ Humulin R™ | ○ Novolin R™
43
Insulin - Short Acting Regular - can be used
in insulin pumps
44
Humulin R - One to three
times daily | 30 minutes before a meal
45
Novolin R - One to three t
times daily | 30 minutes before a meal
46
Insulin - Short Acting Regular - used in conjunction with
h basal/long | acting insulin
47
Insulin - Intermediate Acting (NPH) - Agents
○ Novolin N™ | ○ Humulin N™
48
Human insulin (rDNA origin) in
isophane suspension
49
Insulin - Intermediate Acting (NPH) generaly
Generally administered twice daily but can be further divided ● Generally fewer injections ● NPH = neutral protamine Hagedorn ● Appears cloudy
50
Insulin - Premixed Insulins
○ Novolog 70/30 (aspart protamine + aspart) ○ Humalog 75/25 (lispro protamine + lispro) ○ Humalog 50/50 (lispro protamine + lispro) ○ Novolin 70/30 (NPH + regular insulin) ○ Humulin 70/30 (NPH + regular insulin)
51
Insulin - Premixed Insulins - Fast facts
Generally administered twice daily ● Less flexibility to dose based on meals eaten as with other regimens ● Fewer injections each day ● Appear cloudy